,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2018', 'fs': 'May 2018', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009DyiE2AS'}, 'Id': 'a0POZ000009DyiE2AS', 'Event_Date__c': '2018-05-15', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'May 2018', 'Status_History__c': 'a132P000000ArSeQAK'}, 'change': None}]",May 2018,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2018', 'fs': 'Jun 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009DyiF2AS'}, 'Id': 'a0POZ000009DyiF2AS', 'Event_Date__c': '2018-06-18', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jun 2018', 'Status_History__c': 'a132P000000ArTxQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-neurological-subcommittee-minutes-2018-07.pdf"" target=""_blank"">Neurological Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-neurological-subcommittee-minutes-2018-07.pdf"" target=""_blank"">Neurological Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Jul 2018', 'fs': 'Jul 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Neurological Subcommittee at meeting Wednesday 4 July 2018.', 'fs': 'Clinical advice received from Neurological Subcommittee at meeting Wednesday 4 July 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009DyiG2AS'}, 'Id': 'a0POZ000009DyiG2AS', 'Event_Date__c': '2018-07-04', 'Event_Description__c': 'Clinical advice received from Neurological Subcommittee at meeting Wednesday 4 July 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-neurological-subcommittee-minutes-2018-07.pdf"" target=""_blank"">Neurological Subcommittee minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Jul 2018', 'Status_History__c': 'a132P000000ArUSQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2019', 'fs': 'Oct 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009DyiJ2AS'}, 'Id': 'a0POZ000009DyiJ2AS', 'Event_Date__c': '2019-10-14', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Oct 2019', 'Status_History__c': 'a132P000000B2KdQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2019', 'fs': 'Nov 2019', 'change': None}, 'Event_Description': {'s': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 14 November 2019', 'fs': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 14 November 2019', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009DyiK2AS'}, 'Id': 'a0POZ000009DyiK2AS', 'Event_Date__c': '2019-11-28', 'Event_Description__c': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 14 November 2019', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Nov 2019', 'Status_History__c': 'a132P000000BBc1QAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that, cladribine should be funded only if cost neutral to fingolimod, taking into account that 20% of patients may require redosing with cladribine at 2 years, and the remaining 80% would likely require redosing at 4 years. This recommendation was based on the evidence for efficacy of cladribine, fingolimod being the most likely comparator, and expert opinions regarding retreatment rates.</p>', 'fs': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that, cladribine should be funded only if cost neutral to fingolimod, taking into account that 20% of patients may require redosing with cladribine at 2 years, and the remaining 80% would likely require redosing at 4 years. This recommendation was based on the evidence for efficacy of cladribine, fingolimod being the most likely comparator, and expert opinions regarding retreatment rates.</p>', 'change': None}, 'Published_Discussion': {'s': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered a resubmission from Merck Serono for the use of cladribine (Mavenclad) for the treatment of RRMS. The Committee noted that the application was originally submitted in May 2018 and was considered by the Neurological Subcommittee in July 2019. </p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Neurological Subcommittee had recommended that the application be declined, primarily due to uncertainty regarding treatment sequencing following cladribine therapy. PTAC noted that the supplier had now provided a resubmission responding to the points raised by the Neurological Subcommittee.</p><p>3.5<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that cladribine is now registered with Medsafe for the treatment of RRMS</p><p>3.6<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that cladribine had a different mechanism of action from other funded treatments for Multiple Sclerosis (MS). The Committee noted that the mechanism of action involved a selective and transient reduction in lymphocytes; with a gradual repopulation over 4-years. The Subcommittee considered that this mechanism of action is different to that of fingolimod, which also has the effect of decreasing lymphocyte counts. </p><p>3.7<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the 96-week, double-blind, placebo-controlled, phase 3 CLARITY trial <a href=""https://www.ncbi.nlm.nih.gov/pubmed/20089960"" target=""_blank"">(Giovannoni et al. N Engl J Med. 2010;362:416-26</a>) and the 2-year CLARITY extension (CLARITY EXT) trial (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/28870107"" target=""_blank"">Giovannoni et al. Mult Scler. 2018;24:1594-1604)</a>, which investigated the efficacy and safety of cladribine in patients with relapsing-remitting multiple sclerosis (RRMS).</p><p>3.8<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the relative risk of disease progression with cladribine relative to placebo according to data from CLARITY was 0.67 (time to 3 month sustained change in EDSS score; 10.8 months in the placebo arm and 13.6 months in the cladribine 3.5 mg/kg arm). The Subcommittee noted that the annualised relapse rate in CLARITY was 0.14 for patients who received cladribine 3.5 mg/kg, compared with 0.33 for patients who received placebo.</p><p>3.9<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that of the 1,184 patients who completed CLARITY, 867 were enrolled in the extension, and that there was a duration of gap between CLARITY and CLARITY EXTENSION. The Committee noted that the gap period was distributed across the treatment groups: the median duration was 40.3 weeks and the maximum duration was between 111 weeks and 118 weeks across the groups (range 0.1-118.0 weeks across all groups). The Committee noted that overall, 10.7% of patients experienced a gap duration of <span style="""">⩽</span>4 weeks; 44.8% experienced a gap &gt;4 to <span style="""">⩽</span>43 weeks, and 44.5% had a gap &gt;43 weeks. </p><p>3.10<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the annualised relapse rate (ARR) in patients treated with cladribine 3.5 mg/kg in CLARITY followed by placebo in CLARITY EXTENSION was not significantly different from that in patients who received cladribine 3.5 mg/kg in both CLARITY and CLARITY EXTENSION (0.15 [0.09, 0.21] v 0.10 [0.06, 0.13], p=0.06), and that both groups showed comparable proportions of relapse-free patients (75.6% and 81.2%, respectively, p = 0.28). The Committee considered that it was possible that the longer the duration of treatment gap the less the effectiveness of treatment, but further analysis was needed to confirm this. </p><p>3.11<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered safety data from an integrated analysis of clinical trials and follow up in patients with MS regarding the safety profile of cladribine tablets <a href=""https://www.ncbi.nlm.nih.gov/pubmed/28870107"" target=""_blank"">(Comi et al. Mult Scler. 2018;24:1594-1604)</a>. The Committee noted the overall adjusted treatment-emergent adverse event (Adj-AE) incidence per 100 patient years (Adj-AE/100PY) in the integrated analysis was 103.29 for patients who received cladribine monotherapy compared with 94.26 for patients who received placebo. The rate of serious TEAEs was reported as 3.57 Adj-AE/100 PY compared with 4.00 Adj-AE/100 PY for patients who received cladribine and placebo, respectively. Lymphopenia and herpes zoster were more common in patients receiving cladribine; however, there were no cases of systemic, serious disseminated herpes zoster attributed to treatment with cladribine tablets. The Committee noted that one patient had been reported to have experienced re-activation of tuberculosis and died. The Committee noted that the authors had reported that there was no increase in malignancy rates with cladribine relative to placebo.</p><p>3.12<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that currently there are no head-to-head trials comparing cladribine to a relevant comparator. The Committee considered, based on indirect analysis <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29634596"" target=""_blank"">(Giovannoni G. Curr Opin Neurol. 2018;31:233-43</a>, <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29149804"" target=""_blank"">Siddiqui et al. Curr Med Res Opin. 2018;34:1361-71</a> and <a href=""https://www.ncbi.nlm.nih.gov/pubmed/30786783"" target=""_blank"">Berardi et al. Curr Med Res Opin. 2019;35:1371-8),</a> that cladribine is likely to have similar efficacy to fingolimod. </p><p>3.13<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Neurological Subcommittee had considered that there was a lack of evidence regarding treatment sequencing following cladribine treatment and that it was unclear how patients who exhibit no progression at four years should be treated subsequently, or how patients who relapsed during the treatment period should then be treated.</p><p>3.14<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there is currently no data on treatment sequencing and retreatment. The Committee considered the following summarised expert opinions (provided by a Merck Serono Multiple Sclerosis Advisory Board):</p><p>3.14.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That if cladribine was effective during years 3 and 4, clinicians would be likely to treat again with cladribine rather than to switch therapy; and that less than 20% would require retreatment in years 3 and 4, based either on clinical evidence of relapse or reactivation of disease.</p><p>3.14.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That if there was evidence of disease activity before the end of year 2, a decision to switch or retreat would depend on the clinical situation of the individual patient.</p><p>3.15<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the above estimates of treatment sequencing and retreatment (paragraphs 15.16.1, and 15.16.2), seemed reasonable.</p><p>3.16<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Neurological Subcommittee had considered that pre-treatment with cladribine might increase the risk of progressive multifocal leukoencephalopathy (PML) on subsequent treatment with natalizumab. The Committee noted that <a href=""https://www.medsafe.govt.nz/profs/Datasheet/m/mavencladtab.pdf"" target=""_blank"">the Medsafe data sheet</a> for cladribine provided the following relevant information “In the clinical trial data base of cladribine in MS (1,976 patients, 8,650 patient years) no case of PML has been reported. However, an MRI should be considered before initiating Mavenclad (usually within 3 months). This is particularly recommended if patients are switched from other MS agents that have a risk of PML.” </p><p>3.17<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Supplier had provided the following view in its resubmission regarding pregnancy and cladribine:</p><p>3.17.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That cladribine would be an appropriate high efficacy option for women considering a pregnancy following treatment with cladribine tablets, and that that a pregnancy can start 6 months after the last dose of cladribine tablets in Year 2. Since no further treatment is required in Years 3 and 4, this provides a window of opportunity for pregnancy and breast feeding.</p><p>3.18<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the Supplier’s view regarding pregnancy and cladribine. However, it also noted that cladribine is classified by the <a href=""https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&amp;id=CP-2010-PI-07339-3&amp;d=202001211016933"" target=""_blank"">Australian Therapeutic Goods Administration</a> as Category D in pregnancy and considered that it is therefore unlikely to be an appropriate treatment option for women planning pregnancy.</p><p>3.19<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Neurological Subcommittee considered that if cladribine was listed, approximately 25% of patients receiving fingolimod and dimethyl fumarate may switch due to the convenience associated with administration; however, the majority of patients who would receive cladribine would be treatment-naïve. The Committee noted the Supplier had provided PHARMAC with data from its Australian market access programme, in which 23% of those who received cladribine were treatment-naïve.</p><p>3.20<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that monitoring while on treatment with cladribine included lymphocyte counts and MRI scans in year 3 and 4.</p><p>3.21<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee recommended that cladribine should be funded only if cost neutral to fingolimod, taking into account that 20% of patients may require redosing with cladribine at 2 years, and the remaining 80% would likely require redosing at 4 years. This recommendation was based on the evidence for efficacy of cladribine, fingolimod being the most likely comparator, and expert opinions regarding retreatment rates.</p>', 'fs': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered a resubmission from Merck Serono for the use of cladribine (Mavenclad) for the treatment of RRMS. The Committee noted that the application was originally submitted in May 2018 and was considered by the Neurological Subcommittee in July 2019. </p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Neurological Subcommittee had recommended that the application be declined, primarily due to uncertainty regarding treatment sequencing following cladribine therapy. PTAC noted that the supplier had now provided a resubmission responding to the points raised by the Neurological Subcommittee.</p><p>3.5<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that cladribine is now registered with Medsafe for the treatment of RRMS</p><p>3.6<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that cladribine had a different mechanism of action from other funded treatments for Multiple Sclerosis (MS). The Committee noted that the mechanism of action involved a selective and transient reduction in lymphocytes; with a gradual repopulation over 4-years. The Subcommittee considered that this mechanism of action is different to that of fingolimod, which also has the effect of decreasing lymphocyte counts. </p><p>3.7<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the 96-week, double-blind, placebo-controlled, phase 3 CLARITY trial <a href=""https://www.ncbi.nlm.nih.gov/pubmed/20089960"" target=""_blank"">(Giovannoni et al. N Engl J Med. 2010;362:416-26</a>) and the 2-year CLARITY extension (CLARITY EXT) trial (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/28870107"" target=""_blank"">Giovannoni et al. Mult Scler. 2018;24:1594-1604)</a>, which investigated the efficacy and safety of cladribine in patients with relapsing-remitting multiple sclerosis (RRMS).</p><p>3.8<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the relative risk of disease progression with cladribine relative to placebo according to data from CLARITY was 0.67 (time to 3 month sustained change in EDSS score; 10.8 months in the placebo arm and 13.6 months in the cladribine 3.5 mg/kg arm). The Subcommittee noted that the annualised relapse rate in CLARITY was 0.14 for patients who received cladribine 3.5 mg/kg, compared with 0.33 for patients who received placebo.</p><p>3.9<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that of the 1,184 patients who completed CLARITY, 867 were enrolled in the extension, and that there was a duration of gap between CLARITY and CLARITY EXTENSION. The Committee noted that the gap period was distributed across the treatment groups: the median duration was 40.3 weeks and the maximum duration was between 111 weeks and 118 weeks across the groups (range 0.1-118.0 weeks across all groups). The Committee noted that overall, 10.7% of patients experienced a gap duration of <span style="""">⩽</span>4 weeks; 44.8% experienced a gap &gt;4 to <span style="""">⩽</span>43 weeks, and 44.5% had a gap &gt;43 weeks. </p><p>3.10<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the annualised relapse rate (ARR) in patients treated with cladribine 3.5 mg/kg in CLARITY followed by placebo in CLARITY EXTENSION was not significantly different from that in patients who received cladribine 3.5 mg/kg in both CLARITY and CLARITY EXTENSION (0.15 [0.09, 0.21] v 0.10 [0.06, 0.13], p=0.06), and that both groups showed comparable proportions of relapse-free patients (75.6% and 81.2%, respectively, p = 0.28). The Committee considered that it was possible that the longer the duration of treatment gap the less the effectiveness of treatment, but further analysis was needed to confirm this. </p><p>3.11<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered safety data from an integrated analysis of clinical trials and follow up in patients with MS regarding the safety profile of cladribine tablets <a href=""https://www.ncbi.nlm.nih.gov/pubmed/28870107"" target=""_blank"">(Comi et al. Mult Scler. 2018;24:1594-1604)</a>. The Committee noted the overall adjusted treatment-emergent adverse event (Adj-AE) incidence per 100 patient years (Adj-AE/100PY) in the integrated analysis was 103.29 for patients who received cladribine monotherapy compared with 94.26 for patients who received placebo. The rate of serious TEAEs was reported as 3.57 Adj-AE/100 PY compared with 4.00 Adj-AE/100 PY for patients who received cladribine and placebo, respectively. Lymphopenia and herpes zoster were more common in patients receiving cladribine; however, there were no cases of systemic, serious disseminated herpes zoster attributed to treatment with cladribine tablets. The Committee noted that one patient had been reported to have experienced re-activation of tuberculosis and died. The Committee noted that the authors had reported that there was no increase in malignancy rates with cladribine relative to placebo.</p><p>3.12<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that currently there are no head-to-head trials comparing cladribine to a relevant comparator. The Committee considered, based on indirect analysis <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29634596"" target=""_blank"">(Giovannoni G. Curr Opin Neurol. 2018;31:233-43</a>, <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29149804"" target=""_blank"">Siddiqui et al. Curr Med Res Opin. 2018;34:1361-71</a> and <a href=""https://www.ncbi.nlm.nih.gov/pubmed/30786783"" target=""_blank"">Berardi et al. Curr Med Res Opin. 2019;35:1371-8),</a> that cladribine is likely to have similar efficacy to fingolimod. </p><p>3.13<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Neurological Subcommittee had considered that there was a lack of evidence regarding treatment sequencing following cladribine treatment and that it was unclear how patients who exhibit no progression at four years should be treated subsequently, or how patients who relapsed during the treatment period should then be treated.</p><p>3.14<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there is currently no data on treatment sequencing and retreatment. The Committee considered the following summarised expert opinions (provided by a Merck Serono Multiple Sclerosis Advisory Board):</p><p>3.14.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That if cladribine was effective during years 3 and 4, clinicians would be likely to treat again with cladribine rather than to switch therapy; and that less than 20% would require retreatment in years 3 and 4, based either on clinical evidence of relapse or reactivation of disease.</p><p>3.14.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That if there was evidence of disease activity before the end of year 2, a decision to switch or retreat would depend on the clinical situation of the individual patient.</p><p>3.15<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the above estimates of treatment sequencing and retreatment (paragraphs 15.16.1, and 15.16.2), seemed reasonable.</p><p>3.16<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Neurological Subcommittee had considered that pre-treatment with cladribine might increase the risk of progressive multifocal leukoencephalopathy (PML) on subsequent treatment with natalizumab. The Committee noted that <a href=""https://www.medsafe.govt.nz/profs/Datasheet/m/mavencladtab.pdf"" target=""_blank"">the Medsafe data sheet</a> for cladribine provided the following relevant information “In the clinical trial data base of cladribine in MS (1,976 patients, 8,650 patient years) no case of PML has been reported. However, an MRI should be considered before initiating Mavenclad (usually within 3 months). This is particularly recommended if patients are switched from other MS agents that have a risk of PML.” </p><p>3.17<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Supplier had provided the following view in its resubmission regarding pregnancy and cladribine:</p><p>3.17.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That cladribine would be an appropriate high efficacy option for women considering a pregnancy following treatment with cladribine tablets, and that that a pregnancy can start 6 months after the last dose of cladribine tablets in Year 2. Since no further treatment is required in Years 3 and 4, this provides a window of opportunity for pregnancy and breast feeding.</p><p>3.18<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the Supplier’s view regarding pregnancy and cladribine. However, it also noted that cladribine is classified by the <a href=""https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&amp;id=CP-2010-PI-07339-3&amp;d=202001211016933"" target=""_blank"">Australian Therapeutic Goods Administration</a> as Category D in pregnancy and considered that it is therefore unlikely to be an appropriate treatment option for women planning pregnancy.</p><p>3.19<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Neurological Subcommittee considered that if cladribine was listed, approximately 25% of patients receiving fingolimod and dimethyl fumarate may switch due to the convenience associated with administration; however, the majority of patients who would receive cladribine would be treatment-naïve. The Committee noted the Supplier had provided PHARMAC with data from its Australian market access programme, in which 23% of those who received cladribine were treatment-naïve.</p><p>3.20<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that monitoring while on treatment with cladribine included lymphocyte counts and MRI scans in year 3 and 4.</p><p>3.21<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee recommended that cladribine should be funded only if cost neutral to fingolimod, taking into account that 20% of patients may require redosing with cladribine at 2 years, and the remaining 80% would likely require redosing at 4 years. This recommendation was based on the evidence for efficacy of cladribine, fingolimod being the most likely comparator, and expert opinions regarding retreatment rates.</p>', 'change': None}, 'Published_Application': {'s': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed a resubmission from Merck Serono for funding of cladribine in the treatment of relapsing-remitting multiple sclerosis (RRMS).</p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed a resubmission from Merck Serono for funding of cladribine in the treatment of relapsing-remitting multiple sclerosis (RRMS).</p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Cost Neutral', 'fs': 'Cost Neutral', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2020', 'fs': 'Feb 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 November 2019.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 November 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009DyiL2AS'}, 'Id': 'a0POZ000009DyiL2AS', 'Event_Date__c': '2020-02-25', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 November 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Cost Neutral', 'Formatted_Date__c': 'Feb 2020', 'Published_Recommendation__c': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that, cladribine should be funded only if cost neutral to fingolimod, taking into account that 20% of patients may require redosing with cladribine at 2 years, and the remaining 80% would likely require redosing at 4 years. This recommendation was based on the evidence for efficacy of cladribine, fingolimod being the most likely comparator, and expert opinions regarding retreatment rates.</p>', 'Published_Application__c': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed a resubmission from Merck Serono for funding of cladribine in the treatment of relapsing-remitting multiple sclerosis (RRMS).</p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p>3.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered a resubmission from Merck Serono for the use of cladribine (Mavenclad) for the treatment of RRMS. The Committee noted that the application was originally submitted in May 2018 and was considered by the Neurological Subcommittee in July 2019. </p><p>3.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Neurological Subcommittee had recommended that the application be declined, primarily due to uncertainty regarding treatment sequencing following cladribine therapy. PTAC noted that the supplier had now provided a resubmission responding to the points raised by the Neurological Subcommittee.</p><p>3.5<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that cladribine is now registered with Medsafe for the treatment of RRMS</p><p>3.6<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that cladribine had a different mechanism of action from other funded treatments for Multiple Sclerosis (MS). The Committee noted that the mechanism of action involved a selective and transient reduction in lymphocytes; with a gradual repopulation over 4-years. The Subcommittee considered that this mechanism of action is different to that of fingolimod, which also has the effect of decreasing lymphocyte counts. </p><p>3.7<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered the 96-week, double-blind, placebo-controlled, phase 3 CLARITY trial <a href=""https://www.ncbi.nlm.nih.gov/pubmed/20089960"" target=""_blank"">(Giovannoni et al. N Engl J Med. 2010;362:416-26</a>) and the 2-year CLARITY extension (CLARITY EXT) trial (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/28870107"" target=""_blank"">Giovannoni et al. Mult Scler. 2018;24:1594-1604)</a>, which investigated the efficacy and safety of cladribine in patients with relapsing-remitting multiple sclerosis (RRMS).</p><p>3.8<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the relative risk of disease progression with cladribine relative to placebo according to data from CLARITY was 0.67 (time to 3 month sustained change in EDSS score; 10.8 months in the placebo arm and 13.6 months in the cladribine 3.5 mg/kg arm). The Subcommittee noted that the annualised relapse rate in CLARITY was 0.14 for patients who received cladribine 3.5 mg/kg, compared with 0.33 for patients who received placebo.</p><p>3.9<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that of the 1,184 patients who completed CLARITY, 867 were enrolled in the extension, and that there was a duration of gap between CLARITY and CLARITY EXTENSION. The Committee noted that the gap period was distributed across the treatment groups: the median duration was 40.3 weeks and the maximum duration was between 111 weeks and 118 weeks across the groups (range 0.1-118.0 weeks across all groups). The Committee noted that overall, 10.7% of patients experienced a gap duration of <span style="""">⩽</span>4 weeks; 44.8% experienced a gap &gt;4 to <span style="""">⩽</span>43 weeks, and 44.5% had a gap &gt;43 weeks. </p><p>3.10<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the annualised relapse rate (ARR) in patients treated with cladribine 3.5 mg/kg in CLARITY followed by placebo in CLARITY EXTENSION was not significantly different from that in patients who received cladribine 3.5 mg/kg in both CLARITY and CLARITY EXTENSION (0.15 [0.09, 0.21] v 0.10 [0.06, 0.13], p=0.06), and that both groups showed comparable proportions of relapse-free patients (75.6% and 81.2%, respectively, p = 0.28). The Committee considered that it was possible that the longer the duration of treatment gap the less the effectiveness of treatment, but further analysis was needed to confirm this. </p><p>3.11<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered safety data from an integrated analysis of clinical trials and follow up in patients with MS regarding the safety profile of cladribine tablets <a href=""https://www.ncbi.nlm.nih.gov/pubmed/28870107"" target=""_blank"">(Comi et al. Mult Scler. 2018;24:1594-1604)</a>. The Committee noted the overall adjusted treatment-emergent adverse event (Adj-AE) incidence per 100 patient years (Adj-AE/100PY) in the integrated analysis was 103.29 for patients who received cladribine monotherapy compared with 94.26 for patients who received placebo. The rate of serious TEAEs was reported as 3.57 Adj-AE/100 PY compared with 4.00 Adj-AE/100 PY for patients who received cladribine and placebo, respectively. Lymphopenia and herpes zoster were more common in patients receiving cladribine; however, there were no cases of systemic, serious disseminated herpes zoster attributed to treatment with cladribine tablets. The Committee noted that one patient had been reported to have experienced re-activation of tuberculosis and died. The Committee noted that the authors had reported that there was no increase in malignancy rates with cladribine relative to placebo.</p><p>3.12<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that currently there are no head-to-head trials comparing cladribine to a relevant comparator. The Committee considered, based on indirect analysis <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29634596"" target=""_blank"">(Giovannoni G. Curr Opin Neurol. 2018;31:233-43</a>, <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29149804"" target=""_blank"">Siddiqui et al. Curr Med Res Opin. 2018;34:1361-71</a> and <a href=""https://www.ncbi.nlm.nih.gov/pubmed/30786783"" target=""_blank"">Berardi et al. Curr Med Res Opin. 2019;35:1371-8),</a> that cladribine is likely to have similar efficacy to fingolimod. </p><p>3.13<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Neurological Subcommittee had considered that there was a lack of evidence regarding treatment sequencing following cladribine treatment and that it was unclear how patients who exhibit no progression at four years should be treated subsequently, or how patients who relapsed during the treatment period should then be treated.</p><p>3.14<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there is currently no data on treatment sequencing and retreatment. The Committee considered the following summarised expert opinions (provided by a Merck Serono Multiple Sclerosis Advisory Board):</p><p>3.14.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That if cladribine was effective during years 3 and 4, clinicians would be likely to treat again with cladribine rather than to switch therapy; and that less than 20% would require retreatment in years 3 and 4, based either on clinical evidence of relapse or reactivation of disease.</p><p>3.14.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That if there was evidence of disease activity before the end of year 2, a decision to switch or retreat would depend on the clinical situation of the individual patient.</p><p>3.15<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the above estimates of treatment sequencing and retreatment (paragraphs 15.16.1, and 15.16.2), seemed reasonable.</p><p>3.16<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Neurological Subcommittee had considered that pre-treatment with cladribine might increase the risk of progressive multifocal leukoencephalopathy (PML) on subsequent treatment with natalizumab. The Committee noted that <a href=""https://www.medsafe.govt.nz/profs/Datasheet/m/mavencladtab.pdf"" target=""_blank"">the Medsafe data sheet</a> for cladribine provided the following relevant information “In the clinical trial data base of cladribine in MS (1,976 patients, 8,650 patient years) no case of PML has been reported. However, an MRI should be considered before initiating Mavenclad (usually within 3 months). This is particularly recommended if patients are switched from other MS agents that have a risk of PML.” </p><p>3.17<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Supplier had provided the following view in its resubmission regarding pregnancy and cladribine:</p><p>3.17.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That cladribine would be an appropriate high efficacy option for women considering a pregnancy following treatment with cladribine tablets, and that that a pregnancy can start 6 months after the last dose of cladribine tablets in Year 2. Since no further treatment is required in Years 3 and 4, this provides a window of opportunity for pregnancy and breast feeding.</p><p>3.18<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the Supplier’s view regarding pregnancy and cladribine. However, it also noted that cladribine is classified by the <a href=""https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&amp;id=CP-2010-PI-07339-3&amp;d=202001211016933"" target=""_blank"">Australian Therapeutic Goods Administration</a> as Category D in pregnancy and considered that it is therefore unlikely to be an appropriate treatment option for women planning pregnancy.</p><p>3.19<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the Neurological Subcommittee considered that if cladribine was listed, approximately 25% of patients receiving fingolimod and dimethyl fumarate may switch due to the convenience associated with administration; however, the majority of patients who would receive cladribine would be treatment-naïve. The Committee noted the Supplier had provided PHARMAC with data from its Australian market access programme, in which 23% of those who received cladribine were treatment-naïve.</p><p>3.20<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that monitoring while on treatment with cladribine included lymphocyte counts and MRI scans in year 3 and 4.</p><p>3.21<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee recommended that cladribine should be funded only if cost neutral to fingolimod, taking into account that 20% of patients may require redosing with cladribine at 2 years, and the remaining 80% would likely require redosing at 4 years. This recommendation was based on the evidence for efficacy of cladribine, fingolimod being the most likely comparator, and expert opinions regarding retreatment rates.</p>', 'Status_History__c': 'a132P000000BV3pQAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2023', 'fs': 'Sep 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009DyiO2AS'}, 'Id': 'a0POZ000009DyiO2AS', 'Event_Date__c': '2023-09-15', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2023', 'Status_History__c': 'a13OZ000008C0PSYA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2023', 'fs': 'Sep 2023', 'change': None}, 'Event_Description': {'s': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 17 November 2023', 'fs': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 17 November 2023', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009DyiP2AS'}, 'Id': 'a0POZ000009DyiP2AS', 'Event_Date__c': '2023-09-15', 'Event_Description__c': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 17 November 2023', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2023', 'Status_History__c': 'a13OZ000008C0AyYAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>The Advisory Committee recommended that cladribine be listed only if <strong>cost neutral</strong> to a weighted average of the currently funded RRMS treatments it is likely to displace.</p><p>\xa0</p><p><a href=""https://pharmac.govt.nz/assets/Uploads/2023-11-PTAC-Meeting-record.pdf#page=30"" target=""_blank"">Link to relevant discussion within the meeting record.</a></p>', 'fs': '<p>The Advisory Committee recommended that cladribine be listed only if <strong>cost neutral</strong> to a weighted average of the currently funded RRMS treatments it is likely to displace.</p><p>\xa0</p><p><a href=""https://pharmac.govt.nz/assets/Uploads/2023-11-PTAC-Meeting-record.pdf#page=30"" target=""_blank"">Link to relevant discussion within the meeting record.</a></p>', 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Cost Neutral', 'fs': 'Cost Neutral', 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/assets/Uploads/2023-11-PTAC-Meeting-record.pdf"" target=""_blank"">Link to meeting record.</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/assets/Uploads/2023-11-PTAC-Meeting-record.pdf"" target=""_blank"">Link to meeting record.</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Mar 2024', 'fs': 'Mar 2024', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 17 November 2023.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 17 November 2023.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009DyiR2AS'}, 'Id': 'a0POZ000009DyiR2AS', 'Event_Date__c': '2024-03-28', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 17 November 2023.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://pharmac.govt.nz/assets/Uploads/2023-11-PTAC-Meeting-record.pdf"" target=""_blank"">Link to meeting record.</a></p>', 'Outcome__c': 'Cost Neutral', 'Formatted_Date__c': 'Mar 2024', 'Published_Recommendation__c': '<p>The Advisory Committee recommended that cladribine be listed only if <strong>cost neutral</strong> to a weighted average of the currently funded RRMS treatments it is likely to displace.</p><p>\xa0</p><p><a href=""https://pharmac.govt.nz/assets/Uploads/2023-11-PTAC-Meeting-record.pdf#page=30"" target=""_blank"">Link to relevant discussion within the meeting record.</a></p>', 'Status_History__c': 'a13OZ000008e6TmYAI'}, 'change': None}]",Jun 2018,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2020', 'fs': 'Feb 2020', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009DyiM2AS'}, 'Id': 'a0POZ000009DyiM2AS', 'Event_Date__c': '2020-02-25', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Feb 2020', 'Status_History__c': 'a132P000000BV49QAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2023', 'fs': 'Oct 2023', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009DyiQ2AS'}, 'Id': 'a0POZ000009DyiQ2AS', 'Event_Date__c': '2023-10-02', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Oct 2023', 'Status_History__c': 'a13OZ000002RXDIYA4'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2024', 'fs': 'May 2024', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009DyiS2AS'}, 'Id': 'a0POZ000009DyiS2AS', 'Event_Date__c': '2024-05-14', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'May 2024', 'Status_History__c': 'a13OZ000009z0IwYAI'}, 'change': None}]",Feb 2020,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2019', 'fs': 'Mar 2019', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009DyiH2AS'}, 'Id': 'a0POZ000009DyiH2AS', 'Event_Date__c': '2019-03-02', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2019', 'Status_History__c': 'a132P000000ArcVQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2019', 'fs': 'Aug 2019', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009DyiI2AS'}, 'Id': 'a0POZ000009DyiI2AS', 'Event_Date__c': '2019-08-05', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Aug 2019', 'Status_History__c': 'a132P000000ArhpQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2020', 'fs': 'Jun 2020', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009DyiN2AS'}, 'Id': 'a0POZ000009DyiN2AS', 'Event_Date__c': '2020-06-23', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2020', 'Status_History__c': 'a132P000000BtQpQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2024', 'fs': 'Jun 2024', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000009DyiT2AS'}, 'Id': 'a0POZ000009DyiT2AS', 'Event_Date__c': '2024-06-07', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2024', 'Status_History__c': 'a13OZ00000ArK5BYAV'}, 'change': None}]",Mar 2019,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
